Multiple Myeloma: key endpoint results by drug
The key endpoints of Multiple Myeloma trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Multiple Myeloma page.
PFS, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Belantamab mafodotin | 36.6 | 13.4 (Daratumumab) | — | n 243 | NCT04246047 Phase 3, primary |
| Bortezomib | 11.2 | 7.1 (BTZ+LD-DEX) | — | n 281 | NCT01734928 Phase 3, primary |
| Carfilzomib | 26.3 | 17.6 (Lenalidomide and Dexamethasone (Rd)) | — | n 396 | NCT01080391 Phase 3, primary |
| Elotuzumab | 19.4 | 14.8 (Lenalidomide + Dexamethasone) | — | n 321 | NCT01239797 Phase 3, primary |
| Isatuximab | 11.5 | 6.5 (Pomalidomide + Dexamethasone) | — | n 154 | NCT02990338 Phase 3, primary |
| Ixazomib | 20.6 | 14.7 | +5.9 | n 360 | NCT01564537 Phase 3, primary |
| Lenalidomide | 35.3 | 21.8 | +13.5 | n 351 | NCT01850524 Phase 3, primary |
| Nirogacestat | 3.5 | 9.6 (Belantamab Mafodotin) | — | 0.95mg/kg Q3W + Nirogacestat · n 34 | NCT07084896 Phase 1/2, secondary |
| Panobinostat | 12.0 | 8.8 | +3.2 | n 387 | NCT01023308 Phase 3, primary |
| Plitidepsin | 2.6 | 1.7 (Dexamethasone) | — | n 171 | NCT01102426 Phase 3, primary |
| Pomalidomide | 3.6 | 1.9 (Dexamethasone) | — | n 302 | NCT01311687 Phase 3, primary |
| Selinexor | 13.9 | 9.5 (Bortezomib + Dexamethasone) | — | n 195 | NCT03110562 Phase 3, primary |
| Daratumumab | 46.7b | — | — | n 444 | NCT02541383 Phase 3, primary |
| Elranatamab | 8b | — | — | 1000 mcg/kg SC · n 6 | NCT03269136 Phase 1, secondary |
| Ibrutinib | 8.5b | — | — | n 74 | NCT02902965 Phase 2, primary |
| Idecabtagene vicleucel | 8.9b | — | — | n 137 | NCT03361748 Phase 2, secondary |
| Thalidomide | 46.7b | — | — | n 444 | NCT02541383 Phase 3, primary |
Drugs checked with no result here: 32 not reported, 31 trial running, 2 not posted.
OS, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Belantamab mafodotin | 24 | 22.9 (Pomalidomide Plus Dexamethasone) | — | n 218 | NCT04162210 Phase 3, secondary |
| Bortezomib | 83.0 | 53.6 (Velcade, Melphalan and Prednisone) | — | n 350 | NCT02195479 Phase 3, secondary |
| Carfilzomib | 10.2 | 10 | +0.2 | n 157 | NCT01302392 Phase 3, primary |
| Daratumumab | 67.6 | 51.8 (Lenalidomide, Low-dose Dexamethasone) | — | n 153 | NCT02076009 Phase 3, secondary |
| Elotuzumab | 48.3 | 39.6 (Lenalidomide + Dexamethasone) | — | n 321 | NCT01239797 Phase 3, secondary |
| Isatuximab | 24.6 | 17.7 (Pomalidomide + Dexamethasone) | — | n 154 | NCT02990338 Phase 3, secondary |
| Ixazomib | 53.6 | 51.6 | +2 | n 360 | NCT01564537 Phase 3, secondary |
| Lenalidomide | 39.3 | 31.5 | +7.8 | n 177 | NCT00056160 Phase 3, secondary |
| Panobinostat | 40.3 | 35.8 | +4.5 | n 387 | NCT01023308 Phase 3, secondary |
| Plitidepsin | 11.6 | 8.9 (Dexamethasone) | — | n 171 | NCT01102426 Phase 3, secondary |
| Pomalidomide | 12.5 | 8.1 (Dexamethasone) | — | n 302 | NCT01311687 Phase 3, secondary |
| Selinexor | 36.7 | 32.8 (Bortezomib + Dexamethasone) | — | n 195 | NCT03110562 Phase 3, secondary |
| Ciltacabtagene autoleucel | 27.0b | — | — | n 8 | NCT03548207 Phase 1/2, secondary |
| Elranatamab | 32.9b | — | — | 600 mcg/kg SC · n 6 | NCT03269136 Phase 1, secondary |
| Idecabtagene vicleucel | 28.3b | — | — | n 137 | NCT03361748 Phase 2, secondary |
| Thalidomide | 49.8b | — | — | n 168 | NCT00507416 Phase 3, secondary |
Drugs checked with no result here: 34 not reported, 30 trial running, 2 not posted.
ORR
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Belantamab mafodotin | 41% | 36% (Pomalidomide Plus Dexamethasone) | — | n 218 | NCT04162210 Phase 3, secondary |
| Bortezomib | 90.9% | 73.9% (Velcade, Melphalan and Prednisone) | — | n 350 | NCT02195479 Phase 3, secondary |
| Daratumumab | 43.3% | 39.4% (Daratumumab IV) | — | n 263 | NCT03277105 Phase 3, primary |
| Elotuzumab | 78.5% | 65.5% (Lenalidomide + Dexamethasone) | — | n 321 | NCT01239797 Phase 3, primary |
| Isatuximab | 60.4% | 35.3% (Pomalidomide + Dexamethasone) | — | n 154 | NCT02990338 Phase 3, secondary |
| Ixazomib | 78.3% | 71.5% | +6.8 | n 360 | NCT01564537 Phase 3, secondary |
| Lenalidomide | 78.5% | 65.5% (Lenalidomide + Dexamethasone) | — | n 321 | NCT01239797 Phase 3, primary |
| Nirogacestat | 29% | 38% (Belantamab Mafodotin) | — | 0.95mg/kg Q3W + Nirogacestat · n 34 | NCT07084896 Phase 1/2, primary |
| Plitidepsin | 22.8% | 3.6% (Dexamethasone) | — | n 171 | NCT01102426 Phase 3, secondary |
| Selinexor | 76.4% | 62.3% (Bortezomib + Dexamethasone) | — | n 195 | NCT03110562 Phase 3, secondary |
| Carfilzomib | 82.5%b | — | — | 20/56 mg/m^2 once weekly · n 228 | NCT03859427 Phase 3, primary |
| Ciltacabtagene autoleucel | 97.1%b | — | — | n 68 | NCT03548207 Phase 1/2, primary |
| Elranatamab | 53.3%b | — | — | n 30 | NCT05228470 Phase 2, primary |
| Ibrutinib | 56.8%b | — | — | n 74 | NCT02902965 Phase 2, secondary |
| Idecabtagene vicleucel | 74.5%b | — | — | n 137 | NCT03361748 Phase 2, primary |
| melphalan hydrochloride (Evomela) | 95%ab | — | — | wk 14.2857142857 | NCT01660633 Phase 2, primary |
| Mezagitamab | 47%b | — | — | 600 mg · n 19 | NCT03439280 Phase 1/2, secondary |
| Panobinostat | 62.2%b | — | — | 20 mg TIW · wk 24 · n 82 | NCT02654990 Phase 2, primary |
| Pomalidomide | 23%b | — | — | n 74 | NCT01324947 Phase 3, primary |
| Thalidomide | 73%b | — | — | n 147 | NCT00507416 Phase 3, secondary |
Drugs checked with no result here: 30 not reported, 30 trial running, 2 not posted.
VGPR or better
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Bortezomib | 71.1% | 49.7% (Velcade, Melphalan and Prednisone) | — | n 350 | NCT02195479 Phase 3, secondary |
| Carfilzomib | 72.6% | 56.1% (Carfilzomib + Dexamethasone) | — | n 179 | NCT03275285 Phase 3, secondary |
| Daratumumab | 75.8% | 44.2% (Lenalidomide, Low-dose Dexamethasone) | — | n 281 | NCT02076009 Phase 3, secondary |
| Isatuximab | 31.8% | 8.5% (Pomalidomide + Dexamethasone) | — | n 154 | NCT02990338 Phase 3, secondary |
| Ixazomib | 48.1% | 39% | +9.1 | n 360 | NCT01564537 Phase 3, secondary |
| Lenalidomide | 75.8% | 44.2% (Lenalidomide, Low-dose Dexamethasone) | — | n 281 | NCT02076009 Phase 3, secondary |
| Pomalidomide | 31.8% | 8.5% (Pomalidomide + Dexamethasone) | — | n 154 | NCT02990338 Phase 3, secondary |
| Selinexor | 44.6% | 32.4% (Bortezomib + Dexamethasone) | — | n 195 | NCT03110562 Phase 3, secondary |
| Belantamab mafodotin | 25%b | — | — | 2.5 mg/kg Q3W · n 40 | NCT05064358 Phase 2, secondary |
| Ciltacabtagene autoleucel | 96.6%b | — | — | n 29 | NCT03548207 Phase 1/2, secondary |
| Thalidomide | 37%b | — | — | n 147 | NCT00507416 Phase 3, secondary |
Drugs checked with no result here: 36 not reported, 31 trial running, 4 not posted.
MRD negativity
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Bortezomib | 53.3% | 35.4% (Bortezomib-lenalidomide-dexamethasone (VRd)) | — | n 197 | NCT03652064 Phase 3, primary |
| Carfilzomib | 18.3% | 5.2% (Carfilzomib and Dexamethasone) | — | wk 52 · n 312 | NCT03158688 Phase 3, secondary |
| Daratumumab | 53.3% | 35.4% (Bortezomib-lenalidomide-dexamethasone (VRd)) | — | n 197 | NCT03652064 Phase 3, primary |
| Ixazomib | 59% | 50% | +9 | wk 72 · n 335 | NCT01850524 Phase 3, secondary |
| Lenalidomide | 53.3% | 35.4% (Bortezomib-lenalidomide-dexamethasone (VRd)) | — | n 197 | NCT03652064 Phase 3, primary |
| Ciltacabtagene autoleucel | 100%b | — | — | n 18 | NCT03548207 Phase 1/2, secondary |
| Selinexor | 33.3%b | — | — | wk 12 · n 3 | NCT02780609 Phase 1/2, secondary |
Drugs checked with no result here: 36 not reported, 32 trial running, 7 not posted.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 82 approved or late-stage drugs with a featured trial in Multiple Myeloma were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.